Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review
Latest update (2026-05)
FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]
From General Health Information to Occupational Exposure Concerns
The legacy of general health and science information has long provided a foundation for public understanding of medication risks and benefits. Within this broad context, the dissemination of clinical evidence regarding bisphosphonate therapies, such as Fosamax, has been a routine part of patient education and medical discourse. This heritage emphasizes the importance of informed consent and the monitoring of adverse effects within therapeutic settings. Transitioning from this general health framework to a more specific occupational exposure concern requires a shift in focus. While the initial clinical evidence review centered on patient populations receiving Fosamax for conditions like osteoporosis, the same pharmacological properties that raise concern for osteonecrosis of the jaw in patients also warrant scrutiny in occupational environments. Workers involved in the manufacturing, handling, or administration of bisphosphonate compounds may face unique exposure pathways. These pathways differ from prescribed therapeutic use, involving potential dermal contact, inhalation of particulate matter, or repeated low-level exposure over extended periods. The pivot from a patient-centric clinical review to an occupational health perspective thus reframes the risk assessment: instead of evaluating dose-dependent therapeutic outcomes, the concern becomes chronic, unintended exposure in the workplace. This transition underscores the need for rigorous exposure monitoring and protective measures, moving the discussion from informed patient consent to occupational safety protocols.
Clinical Evidence Linking Fosamax to Osteonecrosis of the Jaw
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but a serious adverse effect—osteonecrosis of the jaw (ONJ)—has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This review examines the clinical evidence linking Fosamax to ONJ, focusing on presentation, pharmacology, mechanistic pathways, risk factors, and causation considerations. Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation typically involves pain, swelling, infection, and exposed bone that persists for weeks to months. Diagnosis is based on clinical examination and imaging, with exclusion of metastatic disease or other causes. The condition can occur spontaneously but is generally linked to dental procedures or trauma (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Multiscale characterization of jawbone tissue has provided insights into its unique responses to bone-related complications, including bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).
Pharmacology and Mechanistic Pathways
Fosamax is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption. Its pharmacology involves high affinity for hydroxyapatite in bone, leading to long-term skeletal retention. The drug accumulates preferentially at sites of high bone turnover, such as the jaw, where it suppresses remodeling. This suppression is thought to impair the ability of the jawbone to repair microdamage and maintain vascularity, contributing to ONJ pathogenesis. Mechanistic pathways linking Fosamax to ONJ include inhibition of osteoclast activity, reduced bone turnover, and potential anti-angiogenic effects. The jawbone's high remodeling rate and exposure to oral microbiota may make it particularly vulnerable (https://pubmed.ncbi.nlm.nih.gov/40345077/). Additionally, bisphosphonates may alter immune responses and promote bacterial colonization, exacerbating infection risk. The time to onset of ONJ symptoms after starting Fosamax varies widely, from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This variability complicates establishing a clear timeline between exposure and harm. In placebo-controlled clinical studies, the percentages of patients with symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ may be rare in the general population but more common in those with additional risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
Risk Factors and Causation Considerations
Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, noting that it has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). It advises that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the label also states that in placebo-controlled studies, symptom rates were similar between groups, which may understate the risk in real-world populations with multiple risk factors. The warning does not specify a threshold duration of use that increases risk, leaving clinicians to rely on clinical judgment. Causation-related considerations for affected patients require careful evaluation. While ONJ is a known adverse effect of bisphosphonates, establishing causation in an individual patient involves assessing temporal relationship, exclusion of other causes, and presence of risk factors. The variable onset—from days to months—makes it difficult to attribute ONJ solely to Fosamax, especially in patients with concurrent dental disease or procedures. Recurrence of symptoms upon rechallenge with the same drug or another bisphosphonate supports a causal link (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief after stopping the drug, further suggesting a drug-related effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ can occur spontaneously, and not all cases are attributable to bisphosphonates. The timeline between exposure and documented harm is influenced by cumulative dose and duration. The label notes that risk may increase with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). For patients on long-term therapy, such as those with osteoporosis, the risk of ONJ should be weighed against the benefits of fracture reduction. The optimal duration of Fosamax use has not been determined, and for low-risk patients, drug discontinuation after 3 to 5 years is considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This guidance may help mitigate ONJ risk.
Summary and Clinical Implications
In summary, clinical evidence supports a causal association between Fosamax and osteonecrosis of the jaw, particularly in patients with additional risk factors such as dental procedures, cancer, or concomitant medications. The mechanistic pathway involves suppressed bone turnover and impaired healing. Warnings in the prescribing information are present but may not fully capture the risk in all populations. Affected patients should consider dental evaluation before starting therapy and discuss the need for drug holidays with their healthcare provider.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is Fosamax and how is it used?
Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).
What is osteonecrosis of the jaw (ONJ) and how is it linked to Fosamax?
What are the risk factors for developing ONJ while taking Fosamax?
Known risk factors include invasive dental procedures, diagnosis of cancer, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, or ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).
How long does it take for ONJ symptoms to appear after starting Fosamax?
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.